Lance Pagliaro
Overview
Explore the profile of Lance Pagliaro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal S, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401675.
PMID: 39965176
Purpose: The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial carcinoma (UC)....
2.
Fizazi K, Le Teuff G, Flechon A, Pagliaro L, Mardiak J, Geoffrois L, et al.
J Clin Oncol
. 2024 Aug;
42(28):3270-3276.
PMID: 39167741
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy...
3.
Rose K, Pham R, Zacharias N, Ionescu F, Paravathaneni M, Marchetti K, et al.
J Natl Cancer Inst
. 2024 Feb;
116(6):966-973.
PMID: 38366627
Introduction: This study investigated the efficacy and safety of neoadjuvant chemotherapy for locally advance penile squamous cell carcinoma for which current evidence is lacking. Methods: Included patients had locally advanced...
4.
Chinniah S, Stish B, Costello B, Pagliaro L, Childs D, Quevedo F, et al.
Int J Radiat Oncol Biol Phys
. 2022 Jul;
114(4):684-692.
PMID: 35878715
Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions,...
5.
Agarwal N, McGregor B, Maughan B, Dorff T, Kelly W, Fang B, et al.
Lancet Oncol
. 2022 Jun;
23(7):899-909.
PMID: 35690072
Background: Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide). We aimed to evaluate cabozantinib, a tyrosine kinase inhibitor with immunomodulatory...
6.
Pal S, McGregor B, Suarez C, Tsao C, Kelly W, Vaishampayan U, et al.
J Clin Oncol
. 2021 Sep;
39(33):3725-3736.
PMID: 34491815
Purpose: COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid tumors. We report results from patients with advanced clear cell (cc) and non-clear cell (ncc) renal cell carcinoma (RCC)....
7.
Fong L, Morris M, Sartor O, Higano C, Pagliaro L, Alva A, et al.
Clin Cancer Res
. 2021 Jun;
27(17):4746-4756.
PMID: 34108181
Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti-PD-L1) +...
8.
Spetsieris N, Boukovala M, Weldon J, Tsikkinis A, Hoang A, Aparicio A, et al.
Clin Genitourin Cancer
. 2020 Jul;
19(1):22-31.e5.
PMID: 32675015
Background: Resistance to novel androgen signaling inhibition and metastatic castration-resistant prostate cancer (mCRPC) progression is likely dependent on tumor microenvironment interactions. The Src pathway and neoangiogenesis have been implicated in...
9.
Boukovala M, Spetsieris N, Weldon J, Tsikkinis A, Hoang A, Aparicio A, et al.
Eur J Cancer
. 2020 Jan;
127:67-75.
PMID: 31986451
Background: The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Here, we report on the testing...
10.
Barrett M, Lenkiewicz E, Malasi S, Stanton M, Slack J, Andrews P, et al.
PLoS One
. 2019 Mar;
14(3):e0213815.
PMID: 30870501
Testicular germ cell tumors (TGCTs) are unique amongst solid tumors in terms of the high cure rates using chemotherapy for metastatic disease. Nevertheless, TGCTs still kill approximately 400 men per...